Ularitide

Summary

Ularitide is a synthetic analogue of the kidney‑derived natriuretic peptide urodilatin. It is being investigated as an intravenous therapy for acute decompensated heart failure (ADHF) and related circulatory disorders. The peptide is intended to promote vasodilation, natriuresis and diuresis, thereby lowering cardiac filling pressures and improving symptoms of dyspnoea.

Mechanism of Action

Ularitide binds the natriuretic peptide receptor‑A (NPR‑A) on vascular smooth muscle and renal tubular cells, activating guanylate cyclase and raising intracellular cGMP. The rise in cGMP produces vasorelaxation, reduces systemic vascular resistance, and enhances glomerular filtration, promoting sodium and water excretion. Concurrently, it suppresses renin‑angiotensin‑aldosterone system activity, contributing to its natriuretic and diuretic actions.

What the Research Shows

Phase II trials in decompensated heart failure showed dose‑dependent reductions in pulmonary capillary wedge pressure, systemic vascular resistance and improvements in cardiac index and dyspnoea scores. A 2018 meta‑analysis of twelve double‑blind ADHF studies (≈600 patients) confirmed a large effect size for lowering pulmonary artery wedge pressure and right atrial pressure versus placebo and other vasoactive drugs. The ongoing Phase III TRUE‑AHF study aims to test clinical outcomes. A small 2024 trial in refractory cirrhotic ascites (n=17) found no benefit on urine output or sodium excretion and reported more adverse events with ularitide.

Reported Benefits

Clinical data indicate that ularitide can rapidly reduce cardiac filling pressures, improve haemodynamic parameters and relieve breathlessness in ADHF without early deterioration of renal function. Meta‑analytic evidence suggests its haemodynamic effects are larger than those of many other vasoactive agents used in the same setting.

Limitations of the Evidence

No mortality or long‑term outcome benefit has been demonstrated; a 2018 review noted that natriuretic peptide agents, including ularitide, failed to show survival advantage. Evidence is limited to short‑term haemodynamic studies and one small ascites trial that showed no efficacy and heightened safety concerns. Ongoing Phase III data are needed to clarify clinical relevance.

Safety Considerations

Across trials, the most common adverse events were dose‑related blood‑pressure reductions and hypotension. The ascites study reported serious hypotensive episodes and a markedly higher rate of adverse reactions compared with placebo. Renal function remained stable in heart‑failure studies but the ascites trial suggested possible renal responsiveness issues. Careful monitoring of blood pressure is essential during infusion.

How It Is Administered

Ularitide is administered intravenously as a continuous infusion, typically over 24–48 hours. Investigated dosing regimens range from 7.5 ng/kg/min to 30 ng/kg/min; some studies used an initial rate of 30 ng/kg/min reduced to 20 ng/kg/min for safety. Formulations are supplied for infusion in a sterile solution.

Routes of Administration

Goals & Uses

• Acute decompensated heart failureCardiovascularModerate
• Natriuresis and diuresisFluid/electrolyte ManagementModerate
• Acute decompensated heart failure treatmentCardiovascularModerate
• Renal protection in heart failureRenalLow
• Systemic vasodilationHemodynamicModerate
• Reduction of cardiac filling pressuresHemodynamicModerate
• RAAS suppressionCardiovascular/EndocrineLow

Contraindications

• Systolic blood pressure < 90 mmHgHemodynamicHigh
• Cardiogenic shock or severe hypotensionCardiovascularHigh
• Known hypersensitivity to ularitideImmunologicHigh
• Severe renal impairment / anuriaRenalModerate
• Hypersensitivity to ularitide or natriuretic peptidesImmunologicalHigh
• Severe hypotensionCardiovascularHigh

Adverse Effects

• HeadacheNeurologicCommonPain in the head or upper neck
• Atrial fibrillationCardiovascularUncommon
• HypotensionCardiovascularCommonLow blood pressure
• Renal dysfunctionRenalRare
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Worsening renal functionRenalUncommon

Drug Interactions

• Loop diureticsLow
• Phosphodiesterase inhibitors (e.g., sildenafil)High
• ACE inhibitors / ARBsModerate
• Other vasodilators (e.g., nitroglycerin)Moderate
• Antihypertensives / vasodilatorsModerate
• DiureticsLowMay worsen dehydration or electrolyte imbalance

Population Constraints

• Pediatric patientsAgeRelative
• Elderly patients (≥75 years)AgeRelative
• Pregnant womenReproductiveRelative
• Patients with severe renal impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization granted.
• United StatesInvestigationalPhase II/III trials ongoing for acute heart failure.
• United KingdomUnapprovedNot licensed.

Not approved by FDA, EMA, or other major regulatory agencies. Development largely discontinued following negative Phase III (TRUE-AHF) results in 2017. Investigated under IND in the US and clinical trial authorization in the EU.

Evidence & Sources

• Ularitide: a natriuretic peptide candidate for the treatment of acutely decompensated heart failure
  Journal ArticleModerateEmani S, et al.2015-01-01T00:00:00.000000Z
• Newer hormonal pharmacotherapies for heart failure
  Journal ArticleModerateYandrapalli S, et al.2018-01-01T00:00:00.000000Z
• Randomized clinical trial on safety of the natriuretic peptide ularitide as treatment of refractory cirrhotic ascites
  Journal ArticleModerateGantzel RH, et al.2024-01-01T00:00:00.000000Z
• Haemodynamic and clinical effects of ularitide in decompensated heart failure
  Journal ArticleModerateMitrovic V, et al.2006-01-01T00:00:00.000000Z
• Randomized double-blind clinical studies of ularitide and other vasoactive substances in acute decompensated heart failure: a systematic review and meta-analysis
  Journal ArticleHighMitrovic V, et al.2018-01-01T00:00:00.000000Z
• Ularitide: from renal natriuretic peptide to clinical trials
  Journal ArticleModerateMeyer M, et al.1996-01-01T00:00:00.000000Z

Frequently Asked Questions